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Abstract High-density lipoprotein (HDL) has a signifi-
cant cardioprotective effects. HDL induces cyclooxygen-
ase-2 (COX-2) expression and prostacyclin I-2 (PGI-2)
release in vascular endothelial cells, which contributes to
its anti-atherogenic effects. However, the underlying
mechanisms are not fully understood. In the present study,
we observed that HDL-stimulated COX-2 expression and
PGI-2 production in human umbilical vein endothelial cells
(HUVECs) in a time- and dose-dependent manner. These
effects triggered by HDL were inhibited by pertussis toxin
(PTX), protein kinase C (PKC) inhibitor GF109203X, and
ERK inhibitor PD98059, suggesting that Gai/Gao-coupled
GPCR, PKC, and ERK pathways are involved in HDL-
induced COX-2/PGI-2 activation. More importantly, we
found that silencing of sphingosine kinase 2 (SphK-2) also
blocked HDL-induced COX-2/PGI-2 activation. In addi-
tion, HDL-activated SphK-2 phosphorylation accompanied
by increased S1P level in the nucleus. Our ChIP data
demonstrated that SphK-2 is associated with CREB at the
COX-2 promoter region. Collectively, these results indi-
cate that HDL induces COX-2 expression and PGI-2
release in endothelial cells through activation of PKC,
ERK1/2, and SphK-2 pathways. These findings implicate a
novel mechanism underlying anti-atherothrombotic effects
of HDL.
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Epidemiological studies have shown that high plasma
levels of high-density lipoproteins (HDLs) protect against
development of atherosclerosis [1]. HDLs up-regulate
endogenous anti-atherogenic molecules, such as prosta-
glandin I-2 (PGI-2), in vascular cells. PGI-2, a vasodilator
that regulates vascular tone [2], also shows anti-athero-
genic properties via inhibiting platelet and leukocyte acti-
vation and adhesion [3]. Several previous studies have
reported that HDLs promote PGI-2 release through cyclo-
oxygenase-2 (COX-2)-dependent mechanism [4, 5]. In
addition, it has been reported that the HDL3 induces COX-
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2 expression and prostacyclin release in human endothelial
cells via a p38 mitogen-activated protein kinase (MAPK)/
CRE-dependent pathway [6]. COX-2, an enzyme respon-
sible for inflammation and pain, has been reported to exert
cardioprotective effects in a model of myocardial ische-
mia–reperfusion injury via activating prostaglandin (PG)
E2 synthesis [7]. Collectively, these findings suggest that
HDLs exert cardioprotective effects at least partially
through activation of COX-2. However, the molecular
mechanisms by which HDLs promote COX-2 expression in
vascular endothelial cells are largely unclear.
Sphingosine 1-phosphate (S1P), a bioactive lysophos-
pholipid, is produced by activated platelets and erythro-
cytes and enters circulation in HDL- or albumin-bound
forms [8, 9]. In particular HDL-bound S1P has been
shown to elicit diverse biological activities, including
vasorelaxation [6], angiogenesis [10], endothelial cell
survival and migration [11], and proliferation of vascular
smooth muscle cells [12]. S1P is produced from phos-
phorylation of sphingosine, which is catalyzed by
sphingosine kinases SphK-1 and SphK-2 [13, 14]. While
SphK-1 and -2 have similar structures with five con-
served domains, they differ in amino terminus and cen-
tral region [15]. They also exhibit different
developmental and tissue expression patterns, and have
distinct kinetic properties [16, 17], which suggest that
they may have a divergent physiological activities.
SphK-1 regulates COX-2 expression through S1P pro-
duction. Studies have shown that activation of protein
kinase C (PKC) by phorbol 12-myristate 13-acetate
(PMA) induces phosphorylation of SphK-1 [18]. Phos-
phorylated SphK-1 translocates to plasma membrane,
resulting in rapid increase in S1P production and COX-2
expression in rat myometrium in late pregnancy [19].
Although SphK-2 is also activated by PKC-dependent
signaling [20], the role of SphK-2 in COX-2 expression
is not clear. SphK-2 is the main SphK isoform in the
nucleus, which regulates nuclear S1P level. In the
nucleus, S1P specifically binds to histone deacetylases
HDAC1 and HDAC2 and inhibits their enzymatic
activity [20]. SphK-2 is associated with HDAC1 and
HDAC2 in repressor complexes and selectively enriched
at promoters of genes encoding cyclin-dependent kinase
inhibitor p21 and transcriptional regulator c-fos, where it
enhances local histone H3 acetylation and promotes
target gene transcription [20]. While SphK-1 promotes
growth and survival, SphK-2 suppresses growth and
enhances apoptosis [21]. Considering that SphK-1 regu-
lates COX-2 expression via S1P production, we specu-
lated that SphK-2 might play a role in HDL-induced
COX-2 expression in vascular endothelial cells via acti-
vating S1P synthesis in the nucleus. In this study, we
investigated whether HDL regulates COX-2 expression
through SphK-2-dependent pathway in human umbilical
vein endothelial cells (HUVECs). Moreover, since cAMP
response element-binding (CREB) protein, a key tran-
scription factor, is involved in transcriptional activation
of COX-2 expression [22], we also investigated the
interaction between CREB and SphK-2.
Materials and methods
Materials
[c-32P]ATP (3,000 Ci/mmol) and [32P]orthophosphate
were purchased from PerkinElmer Life Sciences (Turku,
Finland). HUVECs were purchased from the Medical
Center for Cells, Central South University (Changsha,
China). Pertussis toxin (PTX), NS398, and 40-6-diami-
dino-2-phenylindole were obtained from Sigma (St. Louis,
USA). GF109203X, PD98059, JTE013, and VPC23019
were from Cayman (Michigan, USA). Competitive
enzyme immunoassay kit for 6-keto PGF1a, nuclear and
cytoplasmic protein extraction kit, and chromatin immu-
noprecipitation (ChIP) assay kit were obtained from
Beyotime Institute of Biotechnology (Haimen, China).
Mouse GAPDH was from Boster (Wuhan, China). Rabbit
anti-COX-2 antibodies were from Epitomics (Burlingame,
USA). Rabbit polyclonal anti-SphK-2 and anti-SphK1
antibodies were from Abcam (Cambridge, USA).
P-CREB, ERK1/2, P-ERK1/2, P-PKCa, and PKCa anti-
bodies were from Cell Signaling (Boston, USA). HDL
was purchased from Millipore Corporation (Billerica,
USA). Lipofectamine 2000 was from Invitrogen (Carls-
bad, USA). The small interfering RNA (siRNA) for SphK-
2 was obtained from Ruibo Co., Ltd. (Guangzhou, China).
RealSuper Mixture (with ROX) was obtained from Cowin
Biotech Co., Ltd. (Beijing, China).
Cell culture and labeling of cellular SphK-2
HUVECs were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10 % fetal bovine
serum, 100 U/ml of penicillin, and 100 mg/L of strepto-
mycin at 37 C, 5 % CO2 in a humidified incubator. The
medium was changed every 3 days until cells were con-
fluent. Cells were then incubated for 6 h in serum-free
medium before transfection. Transfected HUVECs were
serum-starved overnight in phosphate-free DMEM, meta-
bolically labeled by incubation in medium containing
[32P]orthophosphate (70 lCi/ml) at 37 C for 4 h, and
subsequently treated with PTX (100 ng/ml, 24 h), JTE013
(10 lmol/L, 1 h), VPC23019 (10 lmol/L, 1 h), PD98059
(10 lmol/L, 1 h), GF109203X (10 lmol/L, 1 h), or their
respective vehicle controls. Cells were then washed once
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with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-
buffered medium and stimulated with HDL.
Quantitation of sphingolipids
Cytoplasm and nuclei were isolated using a Nuclear and
Cytoplasmic Protein Extraction Kit (Beyotime Biotech-
nology, Hangzhou, China) according to the manufacturer’s
instructions. Lipids were extracted and sphingolipids were
determined by liquid chromatography coupled with elec-
trospray ionization–tandem mass spectrometry (LC–ESI–
MS/MS) using LIPID MAPSTM Incinerator calendar pro-
vided by Onyalai Lipids (Alabaster, AL). Internal standards
were added in 0.5-fold quantities.
SphK-2 activity
Cells were lysed by repeated freeze and thaw cycles. SphK-
2 activity in cell lysates was determined in the presence of
1 M KCl, under which SphK-2 exhibits optimal activity,
while SphK-1 is strongly inhibited [23]. In brief, cell
lysates were incubated with 50 lM sphingosine [in the
form of complex with bovine serum albumin (BSA)] and
[c-32P]ATP at 37 C for 30 min. Reactions were stopped
by the addition of 500 ll of chloroform/methanol/con-
centrated HCl (100:100:1, vol/vol). After addition of
100 ll chloroform and 100 ll 2 M KCl for phase separa-
tion, samples were vortexed and centrifuged at 7009g for
5 min. Aliquots (100 ll) of organic phase containing




HUVECs were plated in six-well plates (1 9 106 cells/
well). At 30–50 % confluence, HUVECs were transfected
with 50 or 100 nM of SphK-2 siRNA or scrambled control
siRNA in OptiMEM (Invitrogen, CA, USA) using Lipo-
fectamine 2000 according to manufacturer’s protocol.
Target sequences for human SphK-2 siRNA were 5-CAA
GGCAGCUCUACACUCA-3 (sense) and 3-GUUCCGU
CGAGAUGUGAGU-5 (antisense), and those for scram-
bled control siRNA were 5-CGGCCUACUUCUGCAU
CUA-3 (sense) and 3-GCCGGAUGAAGACGUAGAU-5
(antisense). After 24 h, the medium was replaced with
fresh serum-free DMEM. After another 48 h incubation,
HUVECs were treated with 120 lg/ml of HDL for 8 h.
COX-2 expression and PGI-2 release were determined.
Quantitation of 6-keto PGF1a by competitive ELISA
To measure 6-keto-PGF1a production, HUVECs were
treated with HDL (120 lg/ml) for 8 h, washed twice with
phosphate buffered saline (PBS), and incubated in PBS
buffer containing 0.75 % fatty acid-free BSA and exoge-
nous AA (10 lmol/L) at 37 C, 5 % CO2 for 30 min in a
humidified incubator [6]. PGI-2 release in samples (50 ll
each) was determined according to manufacturer’s
instructions.
Protein extraction
Nuclear and cytoplasmic proteins were extracted using cell
lysis buffer (Beyotime, Haimen, China) according to
manufacturer’s instructions.
Protein analysis by Western blotting
Equal amounts of proteins were separated by 10 % sodium
dodecyl sulfate-based polyacrylamide gel electrophoresis
(SDS–PAGE), and transferred to polyvinylidenedifluoride
(PVDF) membranes. Membranes were incubated with
COX-2, SphK-2, P-CREB, P-PKCa, PKCa, P-ERK1/2,
ERK1/2, and GAPDH antibodies, respectively, washed,
and incubated with anti-rabbit or anti-mouse secondary
antibodies conjugated with horseradish peroxidase for
detection. Immunopositive bands were visualized by
enhanced chemiluminescence and quantified using a den-
sitometer (Molecular Dynamics, Sunnyvale, CA, USA).
Real-time PCR
Total RNA was isolated using TRIzol reagent (Sigma, St.
Louis, USA) and reverse transcribed by random priming
and Moloney Murine leukemia virus reverse transcriptase
(Fermantas, Ontario, Canada) according to manufacturer’s
instructions. Primers specific for human COX-2 and
GAPDH were obtained from Invitrogen (Shanghai, China)
and had sequences as follows: COX-2: 50-TTC AAA TGA
GAT TGT GGG AAA ATT GCT-3 (sense), 50-AGA TCA
TCT CTG CCT GAG TAT CTT-30 (antisense); GAPDH:
50-CAA GGT CAT CCA TGA CAA CTT TG-30 (sense),
50-GTC CAC CAC CCT GTT GCT GTA G-30 (antisense).
mRNA expression levels of COX-2 and GAPDH were
quantified using SYBR Green Master Mix (with ROX) on a
real-time PCR detection system (Applied Biosystems, CA,
USA). mRNA levels of COX-2 were normalized to
GAPDH.
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Immunoprecipitation assays
HUVEC cells cultured for 48 h were harvested by scraping
and lysed in 1 ml lysis buffer (50 mM Tris–HCl, 75 mM
NaCl, 75 mM KCl, 4 mM MgCl2, 1 % NP-40) containing
1X Halt Protease Inhibitor Cocktail (Pierce, Rockford, IL,
USA) [24]. Lysate (500 lg of total protein) was subjected
to immunoprecipitation by incubation with 10 lg of rabbit
polyclonal SphK-1 antibody or rabbit polyclonal SphK-2
antibody in the presence of Protein A?G agarose beads.
Beads were boiled in Laemmli sample buffer to elute
precipitated proteins [24]. Precipitated protein samples
were then separated on 10 % SDS-PAGE gels and trans-
ferred to PVDF membranes. Membranes were incubated
with rabbit anti-p-CREB antibody, rabbit polyclonal SphK-
1 antibody, or rabbit polyclonal SphK-2 antibody, washed,
and incubated with anti-rabbit secondary antibody conju-
gated with horseradish peroxidase for detection.
Chromatin immunoprecipitation (ChIP)
ChIP was conducted using a ChIP assay kit from Beyotime
(Haimen, China) with slight modifications. Immunopre-
cipitated DNA was purified and amplified across the COX-
2 promoter region using 50 primer -119TAA GGG GAG
AGG AGG GAA AAA T-97 and 30 primer ?6ACA ATT
GTC GCT AAC CGA G-14 [25].
Statistical analysis
Data are presented as mean ± SE. Statistical analysis
was performed using Student’s t test or ANOVA ana-
Fig. 1 HDL-induced COX-2 expression and PGI-2 release in HU-
VECs. a, b HUVECs were incubated with PBS (Control group), or
HDL. HUVECs were incubated with different doses of HDL for 8 h,
and the expression of COX-2 was assayed by Western blot analysis
(a). The relative protein expression was normalized to GAPDH (b). c,
d HUVECs were incubated with PBS or HDL (120 lg/ml) at different
time points, and the expression of COX-2 was assayed by Western
blot analysis (c). The relative protein expression was normalized to
GAPDH (d). e HUVECs were incubated with PBS or HDL (120 lg/
ml) at different time points, the production of PGI-2 was determined
by competitive ELISA (e). f The cells were preincubated for 60 min
with or without 10 lM NS398 and then stimulated by HDL (120 lg/
ml). The production of PGI-2 was determined by competitive ELISA
(f). Data were mean ± SE from three separate experiments.
*P \ 0.05 versus Control group
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lysis. Differences with P \ 0.05 were considered statis-
tically significant.
Results
HDL induces COX-2 expression and PGI-2 release
in HUVECs
Vascular endothelial cells play an important role in
many pathological and physiological processes and are
extensively studied in medical research. HUVECs
resemble arterial endothelial cells and are widely used
in studies of vascular endothelial cells, since they are
more easily available than cells from many other
vessels [26]. Since several previous reports have
indicated that HDL activates PGI-2 release through
COX-2-dependent mechanisms [4, 27], we investigated
that the effects of HDL on COX-2 expression and
PGI-2 release in HUVECs. As shown in Fig. 1a–d,
HDL-induced COX-2 protein expression in HUVECs
in a dose (60–120 lg/ml)- and time (2–8 h)-dependent
manner. Maximal COX-2 expression was observed
after 8 h of incubation with 120 lg/ml of HDL. Sim-
ilarly, HDL-activated PGI-2 release into culture med-
ium in a time-dependent manner, presumable by
increasing COX-2-catalyzed PGI-2 production
(Fig. 1e). Indeed, HDL-induced PGI-2 release was
attenuated by NS398, a specific inhibitor of COX-2
(Fig. 1f). Therefore, our results showed that HDL
activates PGI-2 release via inducing COX-2 expression
in HUVECs. Consequently, we investigated that the
molecular mechanisms underlying HDL-induced COX-
2 expression and PGI-2 release.
HDL induces COX-2 expression and PGI-2 release
via PTX-sensitive Gai/Gao proteins
We postulated that S1P receptors coupled to PTX-sensitive
Gai/Gao cells with PTX. Our data showed that incubation
of HUVECs with PTX, a specific inhibitor of Gai/Gao-
protein, prior to HDL treatment markedly attenuated HDL-
induced COX-2 expression (Fig. 2a, b) and PGI-2 release
(Fig. 2c). We, therefore, speculated that S1P receptors
coupled to PTX-sensitive Gai/Gao proteins may mediate
the effects of HDL.
HDL-induced COX-2 expression and PGI-2 release are
PKC- and ERK-dependent
Our results also showed that COX-2 expression and PGI-2
release triggered by HDL were inhibited by GF109203X, a
specific PKC inhibitor (Fig. 3a–c) and PD98059, a ERK
kinase inhibitor (Fig. 3d–f), indicating that PKC- and
ERK-dependent pathways are involved in HDL-induced
COX-2 expression and PGI-2 release in HUVECs.
HDL-induced COX-2 expression and PGI-2 release are
accompanied by PKCa and ERK1/2 activation
HUVECs were treated with 120 lg/ml of HDL for dif-
ferent durations, and activation of PKCa and ERK1/2
was detected by Western blot analysis of protein phos-
phorylation (Fig. 4a). Our results showed that HDL-
activated PKCa and ERK1/2 in a time-dependent man-
ner, with maximal phosphorylation observed at 20 min.
Our Western blotting data further supported that HDL
promotes COX-2 expression and PGI-2 release in HU-
VECs via activating PKCa- and ERK1/2-dependent
pathways.
Fig. 2 Effect of PTX on the HDL-induced COX-2 expression and
PGI-2 release. a–c Cells were washed and pretreated with PBS or
100 ng/ml PTX for 24 h and then stimulated without or with 120 lg/
ml HDL for 8 h. The expression of COX-2 was assayed by Western
blot analysis (a), relative protein expression of COX-2 was normal-
ized to GAPDH, and the production of PGI-2 was determined by
competitive ELISA (c). Data were mean ± SE from three separate
experiments. *P \ 0.05 versus Control group
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HDL induces COX-2 expression and PGI-2 release
via activation of S1P receptors (S1PRs)
S1P receptors are present in the cardiovascular system. S1P
receptors 1–3 (S1PR1–3) are expressed in endothelial cells,
whereas S1PR1–4 are expressed in myocardial tissues [28].
We found that HDL-induced COX-2 expression and PGI-2
release were inhibited by pretreatment with VPC23019, an
inhibitor of S1PR1 and S1PR3, but hardly affected by JTE,
an inhibitor of S1PR2 (Fig. 5a–c). These results suggested
that HDL induces COX-2 expression and PGI-2 release in
HUVECs via activation of S1PR1 and S1PR3.
SphK-2 silencing inhibits HDL-induced COX-2
expression and PGI-2 production
To investigate whether SphK-2 is involved in HDL-
induced COX-2 expression and PGI-2 production, we
studied the effect of SphK-2 silencing by siRNA transfec-
tion. Western blot analysis showed that SphK-2 protein
level was much lower in HUVECs transfected with SphK-2
specific siRNA than those transfected with control siRNA
(Fig. 6a). HUVECs transfected with SphK-2 specific siR-
NA or control siRNA were serum-starved overnight in
phosphate-free DMEM, washed, and treated with 120 lg/ml
Fig. 3 COX-2 expression and PGI-2 release induced by HDL were
inhibited by GF109203X or PD98059 in HUVECs. a–c Cells were
washed and pretreated with PBS or the PKC inhibitor GF109203X
(10 lmol/L) for 1 h, and then stimulated without or with 120 lg/ml
HDL for 8 h. The expression of COX-2 was assayed by Western blot
analysis (a), relative protein expression of COX-2 was normalized to
GAPDH (b), and the production of PGI-2 was determined by
competitive ELISA (c). d, e Cells were washed and pretreated with
PBS or the extracellular regulated kinase (ERK)1/2 inhibitor
PD98059 (10 lmol/L) for 1 h, and then stimulated without or with
120 lg/ml HDL for 8 h. The expression of COX-2 was assayed by
Western blot analysis (d), relative protein expression of COX-2 was
normalized to GAPDH (e), and the production of PGI-2 was
determined by competitive ELISA (f). Data were mean ± SE from
three separate experiments. *P \ 0.05 versus Control group
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HDL or vehicle for different durations. Cells were then
lysed and intracellular levels of COX-2 and PGI-2 were
determined by Western blot analysis and competitive
ELISA, respectively, as described in Materials and Meth-
ods. Our results showed that SphK-2 silencing abrogated
HDL-induced COX-2 expression (Fig. 3b–d) and PGI-2
production (Fig. 3e). These data demonstrated that SphK-2
mediates HDL-induced COX-2 expression and PGI-2
production.
HDL activates SphK-2 and promotes PGI-2 release
via Gai/Gao-, PKC-, and ERK-dependent pathways
The PKC activator, PMA, has been shown to stimulate
SphK-1 by inducing its phosphorylation [18], which is not
only required for translocation of SphK-1 to the plasma
membrane but also for activation of COX-2 gene expression
[18, 19]. In contrast, mechanisms of SphK-2 activation
remain largely unknown. Considering that SphK-1 and
SphK-2 are highly homologous, we investigated whether
SphK-2 is also activated by phosphorylation. HUVECs were
serum-starved overnight in phosphate-free DMEM, meta-
bolically labeled with 32P, incubated with PTX,
GF109203X, or PD98059, and then treated with 120 lg/ml
HDL or vehicle for 20 min. Cell lysates were immunoblotted
with SphK-2 antibody and 32P incorporation was determined
by autoradiography. SphK-2 activity in immunoprecipitates
was also determined. We found that SphK-2 was constitu-
tively phosphorylated, and 32P incorporation was markedly
increased after treatment with HDL. Moreover, HDL-
induced SphK-2 phosphorylation was accompanied by sig-
nificantly increased SphK-2 activity in immunoprecipitates.
Treatment of cells with PTX, GF109203X, or PD98059
markedly inhibited HDL-stimulated increase in SphK-2
activity (Fig. 7a). In addition, level of S1P in the nucleus
increased after treatment with HDL. Incubation with PTX,
GF109203X, or PD98059 markedly attenuated HDL-
induced increase in nuclear S1P concentration. In contrast,
S1P level in extracellular fluid was not affected by HDL
treatment (Fig. 7b). Collectively, these data provided further
evidence that HDL stimulates PGI-2 release by activating
SphK-2, which acts downstream of Gai/Gao-, PKC-, and
ERK in HDL-induced signal transduction.
SphK-2 interacts with CREB
CREB protein, a key transcription factor and downstream
effector of PKC, regulates COX-2 transcription [29].
Fig. 4 Phosphorylation of signaling pathways involved in COX-2
expression and PGI-2 release induced by HDL in HUVECs.
a HUVECs were incubated with 120 lg/ml of HDL at different time
points, and the activation of PKCa and ERK1/2 was analyzed by
Western blot analysis. Protein samples were immunoblotted with anti-
phospho-PKCa, anti-phospho-ERK1/2, anti-total-PKCa, anti-total-
ERK1/2 and anti-GAPDH antibodies
Fig. 5 COX-2 expression and PGI-2 release induced by HDL were
inhibited by different S1P receptors (S1PRs) inhibitors in HUVECs.
a–c Cells were washed and pretreated with PBS or the S1P1 and S1P3
inhibitor VPC23019 (10 lmol/L), or the S1P2 inhibitor JTE013
(10 lmol/L) for 1 h, and then stimulated without or with 120 lg/ml
HDL for 8 h. The expression of COX-2 was assayed by Western blot
analysis (a), relative protein expression of COX-2 was normalized to
GAPDH (b),and the production of PGI-2 was determined by
competitive ELISA (c). Data were mean ± SE from three separate
experiments. *P \ 0.05 versus VPC23019/HDL group
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Although recent reports have indicated that phorbol esters,
activators of PKC, also stimulate SphK-2 activity [20],
there is no evidence that CREB and SphK-2 interacts with
each other. We found that SphK-2 in vascular endothelial
cells contributes to S1P production in the nucleus (Fig. 7b).
In the nucleus, S1P specifically binds to histone deacety-
lases HDAC1 and HDAC2 and inhibits their enzymatic
activity, resulting in activation of target gene transcription
[20]. Whether SphK-2 activates COX-2 gene transcription
via increasing nuclear S1P level is not clear either. To find
out whether there is a direct interaction between CREB and
SphK-2, we conducted immunoprecipitation experiments.
We found that specific pull down of SphK-2 brought down
CREB, but not SphK-1, suggesting that CREB is associated
with SphK-2 (Fig. 8a, b). Furthermore, we studied contri-
bution of SphK-1 and SphK-2 to HDL-induced COX-2
gene expression using ChIP. HUVECs were treated with
HDL (120 mg/ml) for 20 min and then incubated with anti-
SphK-2 antibody or anti-SphK-1 antibody coupled to
agarose beads. Results from ChIP showed that HDL
treatment significantly increased SphK-2-associated, but
not SphK-1-associated COX-2 promoter activity (Fig. 8c),
in agreement with involvement of SphK-2 in HDL-induced
gene expression of COX-2.
Discussion
HDL, arguably the most potent anti-atherogenic factor in
humans, independently predicts epidemiologic risk of
cardiovascular events [30]. HDL cholesterol via promoting
reverse cholesterol transport. In addition, HDL has other
potent anti-atherogenic properties including anti-inflam-
matory, anti-oxidative, anti-apoptotic, and nitric oxide
(NO)-generating activities [1, 31, 32]. The mechanisms by
which HDL exerts its powerful anti-atherogenic effects are
not entirely understood.
Numerous studies have shown that COX-2, a key
enzyme in PG synthesis, is a downstream effector of a
variety of extracellular signaling molecules, including
Fig. 6 Knockdown of SphK-2
reduces COX-2 induction and
PGI-2 release by HDL in
HUVECs. Cells were
transfected with 50 or 100 nM
siRNA of SphK-2. The
expression of SphK-2 was
assayed by Western blot
analysis (a). 48 h after siControl
and siSphK-2 (100 nM)
transfection, cells were treated
with PBS or HDL (120 lg/ml)
for 8 h. The expression of COX-
2 was assayed by Western blot
analysis (b), relative protein
expression of COX-2 was
normalized to GAPDH (c),
COX-2 mRNA levels were
assayed by quantitative real-
time PCR (d), and the
production of PGI-2 was
determined by competitive
ELISA (e). Data were
mean ± SE from three separate
experiments. *P \ 0.05 versus
siControl group
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G-protein-coupled receptor (GPCR) ligands and cyto-
kines [33, 34]. Our results showed that HDL significantly
upregulates COX-2 expression and PGI-2 release in
HUVECs (Fig. 1). These effects of HDL were abrogated
by PTX, an irreversible inhibitor of Gai/Gao proteins
(Fig. 2), GF109203X, a PKC inhibitor, and PD98059, an
ERK inhibitor (Fig. 3), suggesting that Gai/Gao-coupled
GPCR, PKC, and ERK pathways are involved in HDL-
induced COX-2/PGI-2 activation. In particular, our
results are in agreement with previous reports that p38
MAPK and ERK1/2 are involved in upregulation of
COX-2 gene expression by HDL [6, 35]. We also
observed that HDL treatment induced phosphorylation of
PKC and ERK1/2 (Fig. 4), which provided further evi-
dence that PKC and ERK1/2 mediate effects of HDL.
Collectively, these findings suggest that HDL protects
endothelial cells through activation of COX-2/PGI-2
signaling via PKC and ERK1/2 pathways.
It has been reported that HDL binds to and activates
S1PR1–3, which are Gai/ao-coupled GPCRs, leading to
activation of intracellular signaling pathways and COX-2
expression [36]. In this study, we observed that, while
VPC23019, an inhibitor of S1PR1 and S1PR3 signifi-
cantly attenuated HDL-induced COX-2/PGI-2 activation,
JTE013, an inhibitor of S1P2 did not show significant
effect (Fig. 5). These results suggest that effects of HDL
are mainly mediated by S1PR1 and S1PR3 rather than
S1PR2.
Fig. 7 Phosphorylation of SphK-2 and PGI-2 release induced by
HDL were inhibited by different inhibitors in HUVECs. HUVECs
were serum-starved overnight in phosphate-free DMEM and meta-
bolically labeled with 32Pi for 4 h prior to treatment with 100 ng/ml
PTX for 24 h, 10 lmol/L GF109203X for 1 h, 10 lmol/L PD98059
for 1 h,and then stimulated with PBS or with 120 lg/ml HDL for
20 min. Cell lysates were immunobloted with 32P incorporation
determined by autoradiography. SphK-2 activity in the immunoblotes
was determined (a). Lipids were extracted, the S1P level was
determined by LC–ESI–MS/MS (b). Data were mean ± SE from
three separate experiments. *P \ 0.05 versus PTX/HDL,
GF109203X/HDL, PD98059/HDL group
Fig. 8 SphK-2 interacts with CREB. Cells were pulled down as
described under experimental procedures. HUVECs were incubated
with anti-SphK-2 or IgG antibodies coupled to agarose beads.Bound
proteins were analyzed by Western blotting with anti-CREB and
SphK-2 antibodies. 10 lg of total cell lysates from each sample were
also analyzed by immunoblotting with anti-CREB and SphK-2
antibodies as inputs (a). HUVECs were incubated with anti-SphK-1
or IgG antibodies coupled to agarose beads. Bound proteins were
analyzed by Western blotting with anti-CREB and SphK-1 antibodies.
10 lg of total cell lysates from each sample were also analyzed by
immunoblotting with anti-P-CREB and SphK-1 antibodies as inputs
(b). HUVEC cells incubated with anti-SphK1, or SphK2 antibodies
coupled to agarose beads, then treated with vehicle or HDL (120 mg/
ml) for 20 min and mRNA levels of COX-2 were determined by
qPCR and normalized to GAPDH. c Results from at least three
independent experiments conducted in triplicate are shown.
*P \ 0.05, versus cells treated with SphK-1 antibodies group
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In the nucleus, S1P activates target gene expression
by inhibiting histone deacetylases HDAC1 and HDAC2
[20]. Although SphK-1 and SphK-2 both contribute to
S1P production, SphK-2 is the dominant isoform in the
nucleus [37]. SphK-1 has been reported to act down-
stream of PKC and mediates phorbol ester-stimulated
COX-2 expression. Although there is no direct evidence
that SphK-2 regulates COX-2 expression, SphK-2 may
be activated by ERK [38]. In this study, we investigated
the role of SphK-1 and SphK-2 in HDL-induced COX-2/
PGI-2 activation. We found that SphK-2 silencing nearly
abolished HDL-induced COX-2 expression and PGI-2
release in HUVECs (Fig. 6). Furthermore, HDL-induced
phosphorylation of SphK-2, which was accompanied by
increased S1P level in the nucleus (Fig. 7). CREB, a key
transcription factor, regulates COX-2 transcriptional [39].
However, the relation between CREB and SphK-2
remains unclear. Our ChiP data showed that SphK-2 is
associated with CREB at the COX-2 promoter region
(Fig. 8). Collectively, these results suggest that HDL
stimulates COX-2 transcription in HUVECs via SphK-2/
S1P activation in the nucleus. In addition, we found that
specific inhibitors of Gai/ao, ERK1/2, and PKC mark-
edly reduced HDL-induced phosphorylation of SphK-2
(Fig. 7), suggesting that SphK-2 acts downstream of Gai/
ao, ERK1/2, and PKC pathways in HDL-stimulated
signal transduction. Figure 9 is a schematic diagram of
HDL-activated signaling pathways leading to COX-2
expression and PGI-2 release in HUVECs.
Conclusions
In summary, our results provide the first evidence that HDL
induces COX-2 expression and PGI-2 release by SphK-2
phosphorylation and activation. The significance of SphK-
2 in cardioprotective effects of HDL and in lipid metabo-
lism needs to be further investigated.
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